Skip to main content

Table 5 Change in electronic EQ-5D scores from baseline to 3 months follow up by GRS groups, Aug 2018 – Mar 2019 (N = 99)

From: A pilot study on the validity and psychometric properties of the electronic EQ-5D-5L in routine clinical practice

  EQ-5D Utility score (mean ± SD, n) EQ-VAS score (mean ± SD, n) Change in EQ-5D Dimension level with limitation from baseline to 3-month (%)
Baseline 3-month Difference p value* Baseline 3-month Difference p value* Mobility Self-care Usual Activities Pain/Discomfort Depression/Anxiety
GRS Group              
GRS Better 0.58 ± 0.28 (20) 0.76 ± 0.26 (20) 0.18 ± 0.18 (20) < 0.001 65.90 ± 18.13 (20) 76.65 ± 14.00 (20) 10.75 ± 15.33 (20) 0.005 − 15.0% (20) − 15.0% (20) − 15.0% (20) − 40% (20) − 20% (20)
Effect size    0.666     0.664       
GRS Same 0.71 ± 0.23 (44) 0.79 ± 0.17 (44) 0.08 ± 0.17 (44) 0.002 74.59 ± 15.22 (44) 76.32 ± 11.54 (44) 1.73 ± 12.60 (44) 0.368 − 9.1% (44) − 2.3% (44) − 2.3% (44) − 13.6% (44) 0% (44)
Effect size    0.396     0.128       
GRS Worse 0.61 ± 0.27 (35) 0.53 ± 0.30 (35) − 0.08 ± 0.28 (35) 0.092 67.37 ± 15.22 (35) 62.43 ± 18.08 (35) − 4.94 ± 18.31 (35) 0.120 14.3% (35) 2.9% (35) 8.6% (35) 22.9% (35) 2.9% (35)
Effect size    0.280     0.296   p  value#
          < 0.001 < 0.001 < 0.001 0.021 < 0.001
Overall 0.65 ± 0.26 (99) 0.69 ± 0.27 (99) 0.04 ± 0.24 (99) 0.074 70.28 ± 16.33 (99) 71.47 ± 15.97 (99) 1.19 ± 16.24 (99) 0.467 − 2.2% (99) − 2.0% (99) − 1.0% (99) − 6.1% (99) − 3.0% (99)
Effect size    0.151     0.074       
Mean GRS†    0.589**     0.495**       
  1. GRS, global rating scale
  2. *Difference between baseline and 3-month EQ-5D Utility and EQ-5D VAS scores tested by paired t-tests
  3. #EQ-5D-5L dimension responses of moderate, severe and very severe were grouped into the ‘with limitation’ category; difference in proportions among GRS groups tested by Chi-square tests
  4. Correlation between mean GRS score and EQ-5D-5L utility or VAS score, tested by Spearman correlation; **p < 0.001